公开(公告)号：EP4243852A1

公开(公告)日：2023-09-20

申请号：EP21892863.8

申请日：2021-11-12

申请人： Ludwig Institute for Cancer Research Ltd ,  Centre Hospitalier Universitaire Vaudois ,  University of Lausanne

发明人： COUKOS, George ,  IRVING, Melita ,  ZOETE, Vincent

IPC分类号： A61K38/16 ,  A61K38/00 ,  A61P35/00 ,  C07K14/00

公开(公告)号：EP2153231A2

公开(公告)日：2010-02-17

申请号：EP08763158.6

申请日：2008-05-30

申请人： University of Lausanne

发明人： THOME, Margot ,  REBEAUD, Fabien ,  HAILFINGER, Stephan

IPC分类号： G01N33/573 ,  C12Q1/37

CPC分类号： C12Q1/37 ,  C12Q2521/537 ,  G01N2500/02

摘要： The present invention is based on the surprising finding of a proteolytic cleavage function of human Malt1. More particularly, the present invention relates to enzyme and screening assays, methods for assessing cleaving activity, methods for screening, isolated polypeptides, antibodies and inhibitors of Malt1. The present invention also relates to the use of Malt1 as a proteolytic enzyme and the use of compounds comprising a peptide comprising an amino acid sequence according to any one of SEQ ID NO: 1-47 as substrates susceptible for specific proteolytic cleavage.

公开(公告)号：EP0938571B1

公开(公告)日：2008-05-07

申请号：EP97948802.0

申请日：1997-10-24

申请人： Novartis AG ,  University of Lausanne ,  Swiss Institute for Allergy and Asthma Research ,  INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER ISREC ,  Novartis Pharma GmbH

发明人： TERSKIKH, Alexey ,  CRAMERI, Reto ,  MACH, Jean-Pierre ,  LE DOUSSAL, Jean-Marc ,  KAJAVA, Andrey

IPC分类号： C12N15/62 ,  C07K19/00

CPC分类号： C07K14/78 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/73 ,  C12N15/62

摘要： The present invention concerns an oligomer comprising more than 2 units, wherein each unit comprises a peptidic domain capable of oligomerizing and a domain capable of binding to an acceptor (ligand), wherein the oligomerizing domain is not an antibody or a functional antibody fragment from the constant region. Also described is the use and synthesis of this oligomer.

公开(公告)号：EP1511763A2

公开(公告)日：2005-03-09

申请号：EP03740980.2

申请日：2003-06-06

申请人： University of Lausanne

发明人： BONNY, Christophe

IPC分类号： C07K5/068 ,  C07K5/09 ,  C07K5/11 ,  C07K7/06 ,  C07K14/47 ,  C07K1/04 ,  A61K47/48 ,  A61K38/05 ,  A61K38/08 ,  A61K38/10 ,  A61P5/48

CPC分类号： C07K5/1016 ,  A61K38/00 ,  A61K47/60 ,  A61K47/62 ,  A61K47/65 ,  C07K1/047 ,  C07K5/1013 ,  C07K5/1019 ,  C07K5/1021 ,  C07K7/06 ,  C07K7/08 ,  C07K2319/00 ,  Y10S530/81

摘要： The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.

公开(公告)号：EP1248571A1

公开(公告)日：2002-10-16

申请号：EP01942530.5

申请日：2001-01-18

申请人： University of Lausanne

发明人： VON SEGESSER, Ludwig, K.

IPC分类号： A61B17/34

CPC分类号： A61M25/0023 ,  A61B17/3431 ,  A61B17/3439

摘要： Provided is a high performance cannula having a proximal end, a distal end, and a lumen extending between the proximal and distal ends, wherein the diameter of the lumen of the cannula can be varied to take into account differences in the diameter of access and target vessels during cannulation. The cannula is characterized by a narrow diameter at the point of insertion that does not adversely impact the flow rate of fluids through the cannula. The cannulas according to this invention produce a small access aperture and are characterized by flow rates that are at least as effective as those of conventional cannulas that produce larger access apertures.

公开(公告)号：EP4396823A1

公开(公告)日：2024-07-10

申请号：EP22772834.2

申请日：2022-08-30

申请人： University of Lausanne

发明人： ZOETE, Vincent ,  PEREZ, Marta ,  MAYOL RULLAN, Francesca

IPC分类号： G16B20/30 ,  G16B40/20

CPC分类号： G16B20/30 ,  G16B40/20

公开(公告)号：EP2288337A1

公开(公告)日：2011-03-02

申请号：EP09742543.3

申请日：2009-05-06

申请人： University of Lausanne

发明人： BERGER, Mette

IPC分类号： A61K9/00 ,  A61K33/00 ,  A61K33/04 ,  A61K33/16 ,  A61K33/18 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34 ,  A61P13/12 ,  A61P17/02 ,  A61P37/00 ,  A61P43/00

CPC分类号： A61K33/26 ,  A61K9/0029 ,  A61K33/04 ,  A61K33/16 ,  A61K33/18 ,  A61K33/24 ,  A61K33/30 ,  A61K33/34 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention addresses the problem of acute deficiencies of trace elements observed in critically ill patients and/or patients receiving parenteral nutrition - toxicity issues are intergrated. In order to solve the problem, the invention provides a kit for parenterally administrating trace elements to a patient, the kit comprising a basic unit of trace elements and at least one supplementary unit, the supplementary unit comprising supplementary trace elements so as to address the specific needs in trace elements of a specific patient. According to an embodiment, the invention provides a supplementary unit for patients diagnosed with SIRS, suffering from burns, patients on continuous renal replacement therapy and patients residing in selenium-poor countries.

公开(公告)号：EP2015073A1

公开(公告)日：2009-01-14

申请号：EP07112228.7

申请日：2007-07-11

申请人： University of Lausanne

发明人： Thome, Margot ,  Rebeaud, Fabien ,  Hailfinger, Stephan

IPC分类号： G01N33/573 ,  C12Q1/37

CPC分类号： C12Q1/37

摘要： The present invention is based on the surprising finding of a proteolytic cleavage function of human Maltl. More particularly, the present invention relates to enzyme and screening assays, methods for assessing cleaving activity, methods for screening, isolated polypeptides, antibodies and inhibitors of Maltl. The present invention also relates to the use of Maltl as a proteolytic enzyme and the use of compounds comprising a peptide comprising an amino acid sequence according to any one of SEQ ID NO: 1-44 as substrates susceptible for specific proteolytic cleavage.

摘要翻译： 本发明基于人类Maltl蛋白水解切割功能的惊人发现。 更具体地，本发明涉及酶和筛选测定法，评估切割活性的方法，筛选方法，分离的多肽，抗体和Malt1抑制剂。 本发明还涉及Maltl作为蛋白水解酶的用途，以及包含含有根据SEQ ID NO：1-44中任一项所述的氨基酸序列的肽的化合物作为易于特异性蛋白水解切割的底物的用途。

公开(公告)号：EP0938571B8

公开(公告)日：2008-07-02

申请号：EP97948802.0

申请日：1997-10-24

申请人： University of Lausanne ,  Swiss Institute for Allergy and Asthma Research ,  INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER ISREC ,  Novartis Pharma GmbH

发明人： TERSKIKH, Alexey ,  CRAMERI, Reto ,  MACH, Jean-Pierre ,  LE DOUSSAL, Jean-Marc ,  KAJAVA, Andrey

IPC分类号： C12N15/62 ,  C07K19/00

CPC分类号： C07K14/78 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/73 ,  C12N15/62

公开(公告)号：EP1529117A2

公开(公告)日：2005-05-11

申请号：EP03784431.3

申请日：2003-08-08

申请人： University of Lausanne

发明人： MOREILLON, Philippe ,  QUE, Yok, Ai ,  AELLEN, Steve

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6888 ,  C12Q1/6818 ,  C12Q1/6851 ,  C12Q1/689

摘要： Overall ratios of ribosomal DNA and ribosomal RNA in microorganisms following exposure to an antimicrobial is shown to correspond to the presence and viability of the microorganism. Methods are provided to assess the presence and viability of microorganisms, by administering an antimicrobial to a population of microorganisms having a first and second marker, quantifying the first and second markers, and determining the ratio between the quantity of the first and second marker. A concordant result indicates the presence of viable microorganisms, whereas a discordant result indicates the presence of non-viable microorganisms.